|
Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)
|
3 Months Ended | 9 Months Ended | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
USD ($)
|
Sep. 30, 2011
USD ($)
|
Sep. 30, 2012
USD ($)
|
Sep. 30, 2012
KRW
|
Sep. 30, 2011
USD ($)
|
Feb. 29, 2012
Samsung Biosimilar Agreement [Member]
USD ($)
|
Feb. 29, 2012
Samsung Biosimilar Agreement [Member]
KRW
|
Sep. 30, 2012
Samsung Biosimilar Agreement [Member]
USD ($)
|
Sep. 30, 2012
Samsung Biosimilar Agreement [Member]
USD ($)
|
Sep. 30, 2012
Samsung Biosimilar Agreement [Member]
KRW
|
|
| Schedule of Equity Method Investments [Line Items] | ||||||||||
| Contribution from Samsung to develop, manufacture and market bio-similar pharmaceuticals | $ 250,000,000 | 280,500,000,000 | ||||||||
| Variable interest entity, qualitative or quantitative information, ownership percentage | 85.00% | 85.00% | ||||||||
| Contribution from Biogen Idec to develop, manufacture and market biosimilar pharmaceuticals | 29,500,000 | 29,500,000 | 32,600,000,000 | 45,000,000 | 49,500,000,000 | |||||
| Percentage of stake in entity minimum | 15.00% | 15.00% | ||||||||
| Percentage of stake in entity maximum | 49.90% | 49.90% | ||||||||
| Payments to Acquire Equity Method Investments | 32,100,000 | 36,000,000,000 | ||||||||
| Remaining obligation of financing arrangements | 12,200,000 | 12,200,000 | 13,500,000,000 | |||||||
| Remaining obligation of financing arrangements due within the next year | 6,400,000 | 6,400,000 | 7,100,000,000 | |||||||
| Recognized loss | (1,258,000) | 0 | (1,769,000) | 0 | ||||||
| Revenue related to technical development and technology transfer services | 4,300,000 | 9,900,000 | ||||||||
| Revenue related to manufacturing agreement | $ 0 | |||||||||